Breast cancer originates most commonly from the inner lining of milk ducts or the lobules that supply the ducts. Cancers originating from ducts are known as ductal carcinomas, while those originating from lobules are known as lobular carcinomas. Carcinoma breast is the commonest malignancy of females all over the world and second leading cause of death due to cancer among females. Worldwide, breast cancer accounts for 22.9% of all cancers (excluding non-melanoma skin cancers) in women.
INTRODUCTION
Breast cancer originates most commonly from the inner lining of milk ducts or the lobules that supply the ducts. 1 Cancers originating from ducts are known as ductal carcinomas, while those originating from lobules are known as lobular carcinomas. Carcinoma breast is the commonest malignancy of females all over the world and second leading cause of death due to cancer among females. Worldwide, breast cancer accounts for 22.9% of all cancers (excluding non-melanoma skin cancers) in women.
2 Prognosis and survival rates for breast cancer vary greatly depending on the cancer type, stage, treatment, and geographical location of the patient.
The proto-oncogene HER-2/neu (C-erbB-2) has been localized to chromosome 17q and encodes a transmembrane tyrosine kinase growth factor receptor. The name for the HER-2 protein is derived from human epidermal growth factor receptor, as it features substantial homology with the epidermal growth factor receptor (EGFR). 3, 4 HER-2/neu protein is a component of a four-member family of closely related growth factor receptors, including EGFR or HER-1 (erb-B1); HER-2 (erb-B2); HER-3 (erb-B3) and HER-4 (erb-B4) 5 . Amplification of the HER-2 gene or over-expression of its protein product is present in 25% to 30% of breast cancers. 6, 7 This study plans to co-relate Her-2/ neu receptor positive breast carcinoma with the history of presentation of the disease, clinical staging, histopathological staging and aggressiveness of the disease in context to eastern Indian population.
The aim of the study was to determine the incidence of Her-2 /neu over-expression (defined as Her-2-positive +++ on IHC), to compare risk factors between Her-2 positive and negative breast cancer patients, to compare clinical stage (TNM) between Her-2 positive and negative breast cancer patients, to compare pathological stage (for M0) and grade between her-2 positive and negative breast cancer, to compare the response to neoadjuvant chemotherapy between Her2/neu positive and negative patients in locally advanced breast cancer. 
METHODS

Study
Response to neo-adjuvant chemotherapy
The response to neoadjuvant chemotherapy for down staging locally advanced tumours will be recorded in terms of reduction in T-size and N-status.
Study technique
 50 patients presenting with malignant breast lump meeting inclusion and exclusion criteria were included in the study 
RESULTS
Incidence of HER-2/neu over-expression (HER -2 -positive +++ on IHC)
In this study, it was found that 15 (30 %) out of 50 cases were HER-2/neu positive and 35 (70%) cases were Her-2/neu negative, although there is a wide variation (15-35%) in HER-2/neu over-expression and amplification. 
Age distribution
In my study of 50 patients of breast cancer, Her-2/neu overexpression is present in 8 cases of <40 years of age group and in 7 cases of >40 years of age group (Table 1) . Here, the p-value is 0.0434 (< 0.05), which is statistically significant.
Distribution of study population according to menstrual status
HER-2/neu receptor over-expression was present in 8 out of 16 Premenopausal women and 7 out of 34 postmenopausal women.
Distribution of study population according to HER-2/neu status and age at menarche
HER-2/neu receptor over-expression was present in 9 out of 25 patients in whom menarche occurred below the age of 12 years of age and 6 out of 25 patients in whom menarche occurred above or equal to the age of 12 years. The p-value is 0.5371 (>0.05), which is statistically insignificant. Distribution of study population according to HER-2/neu status and age at menopause HER-2/neu receptor over-expression was present in 4 out of 16 patients in whom menopause occurred below the age of 45 years and 3 out 18 patients in whom menopause occurred above or equal to the age of 45 years Table 3 .
Distribution of study population according to HER-2/neu status and number of full term pregnancy
HER-2/neu receptor over-expression was present in 7 cases bearing two or less children & in 3 cases bearing more than two children. Here, the p-value is 0.5142(>0.05), which is statistically insignificant.
Distribution of study population according to HER-2/neu status and age at first full term pregnancy
Out of 8 women of age at first full term pregnancy at >25 years of age 3 had HER-2/neu receptor over-expression and Out of 33 women of age at first full term pregnancy at ≤ 25 years of age 7 had HER-2/neu receptor overexpression. Here, the p-value is 0.6145 (> 0.05), which is statistically insignificant. (Table 5) . Here, the p-value is 0.5007 (>0.05), which is statistically insignificant. Table 6 ).
Distribution of study population according to ER and HER-2/neu status
In our study 54% (n = 27) patients, had ER positive status and 46% (n=23) patients had ER negative status. HER-2/neu receptor over-expression was present in 3 out of 27 ER positive cases and 12 out of 23 ER negative cases. Here, the p-value is 0.0044 (< 0.05), which is statistically significant.
Distribution of study population according to Pr and HER-2/Neu status
In our study 52% (n = 26) patients had PR positive status and 48% (n = 24) patients had PR negative status.HER-2/neu receptor over-expression was present in 4 out of 26 PR positive cases and 11 out of 24 PR negative case. Here, the p-value is 0.0415 (<0.05), which is statistically significant ( Table 7) .
Distribution of study population according to HER-2/Neu status and laterality of breast carcinoma
HER-2/neu receptor over-expression was present in 8 out of 15 in right sided breast carcinoma patients, 5 out of 15 in Lt sided breast carcinoma patients and 2 out of 15 in Both sided breast carcinoma patients.
Distribution of study population according to HER-2/Neu status and clinical stage (Tnm) such as number of early breast cancer/ locally advanced breast cancer/metastatic breast cancer
Out of 11 early breast cancer patients HER-2/neu receptor over-expression was present in 1 case, out of 19 locally advanced breast cancer patients HER-2/neu receptor over-expression was present in 6 cases and out of 20 metastatic breast cancer patients HER-2/neu receptor over-expression was present in 8cases (Table 8) .
Distribution of study population according to HER-2/neu status and T-size of breast carcinoma
Out of 19 women with tumour size ≤ 5 cm HER-2/neu overexpression was in 2 cases and Out of 31 women with tumour size >5 cm HER-2/neu over-expression was in 13 cases. 
Distribution of study population according to HER-2/neu status and breast carcinoma grade
Association of HER-2/Neu receptor status with tumour grade HER-2/neu protein receptor over-expression was present in nil out of 9 in grade I tumour, 7 out of 24 in grade II tumours and 8 out of 17 in grade III tumours ( Table 9) .
Distribution of study population according to HER-2/neu status and lymphovascular invasion of breast carcinoma
Lymphovascular invasion is present in 8 out of 15 HER-2/neu Positive cases and in 8 out of 35 HER-2/neu negative cases. In both the cases p value is significant. 
Distribution of study population according to HER-2/neu status and skin-nipple areola involvement of breast carcinoma
Skin-nipple areola involvement is present in 4 out of 15 HER-2/neu Positive cases and in 8 out of 35 HER-2/neu negative cases (Table 10 ). 
Distribution of study population according to HER-2/neu status and lymphocytic infiltration of breast carcinoma
Lymphocytic infiltration was present in 3 out of 15 HER-2/neu positive cases and in 6 out of 35 HER-2/neu negative cases.
Distribution of study population according to her-2/neu status and number of lymph node involved in breast carcinoma
Out of 12 lymph node negative patients only 2 have HER-2/neu over-expression, out of 10 patients involving 1-3 lymph nodes only 1 has HER-2/neu overexpression, out of 17 patients involving 4-9 lymph nodes only 5 have HER-2/neu over-expression and out of 11 patients involving >9 lymph nodes 7 have HER-2/neu overexpression (Table 11) .
Distribution of study population according to HER-2/neu status and response to neo-adjuvant chemotherapy of breast carcinoma
Out of 15 HER-2/neu receptor over-expression patients only 1 patient responded to neo-adjuvant chemotHERapy and out of 35 HER-2/neu Negative patients only 6 patients responded to neo-adjuvant chemotherapy Table  12 .
DISCUSSION
Incidence of her-2/neu over-expression (Her-2/neu positive +++ on IHC)
In our study, we found that 15(30 %) out of 50 cases were HER-2/neu positive and 35 (70%) cases were HER-2/neu negative. This is in agreement with various studies where HER-2/neu or its protein P185 is over-expressed in 10-35% of breast cancer patients in the western population an over amplification of this gene in 25-30%, have been reported. [8] [9] [10] Age at presentation
In our study HER-2/neu overexpression was associated with younger age. This is in agreement with the study done by Rilke F et al, who found -HER-2/neu overexpression is associated with young age.
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Menstrual status
In our study HER-2/neu receptor over-expression was present in 8 out of 16 premenopausal women and 7 out of 34 post-menopausal women.
Khorshid et al and Al-moundhri et al in their respective studies reported no association between HER2/neu immunopositivity and menopausal state and thereby showed similar results to our study. 12, 13 Age at menarche, age at menopause Our finding regarding the age at Menarche and Menopause is corroborative with a retrospective analysis of breast cancer cases conducted by Siddiqui T et al, who showed the age of menarche and the age of Menopause has no statistical significance between the HER-2/neu positive and the HER-2/neu negative Breast cancer in the population. 14 Number of full term pregnancy, age at first full term pregnancy, parity, family history of ovarian/breast cancer among first degree relatives, site of lump (left /right/bilateral), skin-nipple areola involvement. All of these have insignificant association with Her-2/neu receptor over-expression.
Our finding is corroborative with a retrospective analysis of Breast Cancer cases conducted by Siddiqui T et al who showed similar results -that the number of full term pregnancy and the age of first full term pregnancy, parity, family history of ovarian and breast cancer, laterality, and skin-nipple-areola involvement had no statistical significance between HER-2/neu positive and negative breast cancer in the population. 
Hormone receptor status -ER/PR
It has significant relationship with It has insignificant relationship with HER-2/neu receptor over-expression. Our finding is corroborative with the several studies. Alahwal et al in his study has mentioned this inverse association between HER-2/neu and ER status. 15 In his study HER-2/neu was positive in only 19.5% of cases with positive ER status versus 80.5% of cases with negative ER status.
History of oral contraceptive
Her-2/neu receptor over-expression was present in 8 out of 26 patients who used OCP and 7 out of 24 patients who did not use OCP in our study. Though it is statistically insignificant, there is positive co-relation between HER-2/neu overexpression and use of oral contraceptive pill.
On the basis of case-case comparisons of 72 Swedish, premenopausal breast cancer patients, Olsson et al reported that breast cancer with HER-2/neu amplification (31% of all cases) was positively associated with early oral contraceptive use (20 years).
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Tumour size
Out of 19 women with tumour size ≤ 5 cm HER-2/neu overexpression was seen in 2 cases and Out of 31 women with tumour size >5 cm HER-2/neu over-expression was seen in 13 cases. HERe, the p-value is 0.0419 (<0.05), which is statistically significant. Our findings corroborate with the other similar studies. Nidam M et al found HER-2 neu positivity in 35% patients with tumour size >5cms. 16 
Degree of differentiation or grade
In our study higher-grade tumours were more likely to demonstrate HER-2/neu amplification than lower grade. Our finding is also corroborative with the study on Breast Cancer cases by Hoff et al, who reported higher-grade tumours were more likely to demonstrate Her-2/neu amplification than lower grade ductal carcinomas (p < 0.001).
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Lymph node: number
In our study it is found that there is Positive co-relation between HER-2/neu over-expression and increased number of lymph node involvement. Our finding is corroborative with several studies. Tokatli F in 2005 from Turkey has reported 20% of his patients positive for HER-2/neu and a significant association was observed between HER-2/neu and increasing number of involved axillary lymph nodes (p = 0.014).
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Response to neo-adjuvant chemotherapy
In the present study-out of 15 Her-2/neu receptor overexpression patients only 1 patient responded to neoadjuvant chemotherapy and out of 35 HER-2/neu Negative patients only 6 patients responded to neoadjuvant chemotherapy. Here, the p-value is 0.5936 (>0.05), which is statistically insignificant. Our finding is corroborative with other studies. HER2/ neu receptor over-expression has also been linked to CMF (cyclophosphamide, methotrexate, 5 -fluorouracil) resistance in clinical trials and taxol resistance in cell line.
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CONCLUSION
HER-2/neu overexpressing breast cancers have increased invasive and metastatic capability and are less responsive to chemotherapy. They have increased risk of recurrence and patients with these tumours have a reduced survival compared with patients with normal levels of HER2/neu.
